Benchmark reiterates Warner Brothers Discovery stock rating at Hold

Warner Bros. Discovery faces a negative box-office update as Supergirl opened to $38 million domestically, below reduced expectations of $50 million to $55 million, with global totals around $68 million and a potential $150 million loss on the release. Benchmark kept a Hold rating, while InvestingPro flagged the stock as overvalued and unprofitable, with 5 analysts recently cutting earnings estimates. The Paramount Skydance takeover remains in focus amid EU, UK, and U.S. regulatory scrutiny and shareholder pushback on executive pay.

Analysis

The market is beginning to separate WBD’s operating asset value from its event-driven takeover optionality, and that gap is where positioning should focus. A box-office miss does not matter much to intrinsic value if a deal closes, but it does matter because it reinforces the view that the standalone asset base is less monetizable than bulls had hoped, which can weaken negotiating leverage if regulators force concessions or delay timing.

Second-order impact: the real beneficiaries of this disappointment are competing studio slates and premium content distributors that can absorb audience share without carrying WBD’s balance-sheet overhang. A weaker theatrical result also pressures the broader IP monetization thesis, which can spill into lower expectations for adjacent releases and reduce confidence in the economics of high-budget franchise films across the sector.

The biggest catalyst is not the film loss; it is the regulatory path. The market is likely underpricing time risk: even if approval ultimately happens, a drawn-out EU/UK/US review can push close timing out by one or two quarters and raise the probability of behavioral remedies, a state lawsuit, or a repricing of terms. That creates a classic event-spread setup where headline risk is asymmetric to the downside over the next 1-3 months, even if the long-run deal still closes.

Contrarian view: the stock may not be as cheap as it looks because the current price appears to embed near-certain transaction value without fully discounting the legal/regulatory friction and execution drag. If the deal wobbles, the equity has to stand on underlying fundamentals that remain weak, so downside in a broken-deal scenario is much larger than the market seems to acknowledge.

Key Decisions for Investors

• Short WBD common into regulatory headlines over the next 2-6 weeks; use a tight stop if the spread tightens materially on confirmed approvals.
• Preferred expression: buy WBD downside via 1-3 month puts or put spreads to capture delay risk while capping premium outlay; target payoff is driven by a 10-20% de-rating if legal risk escalates.
• Pair trade: long a more insulated content/licensing peer versus short WBD to isolate regulatory/event risk from sector beta; this works best if the acquisition timeline slips rather than breaks.
• If already long WBD for deal consideration, hedge with short-dated puts into known decision dates from the EU/CMA/state litigation calendar.
• Watch for a failed or delayed close as a catalyst to re-underwrite from standalone cash burn and governance overhang; in that scenario the equity should trade on fundamentals, not rumored deal value.